|Bid||29.07 x 800|
|Ask||31.10 x 1400|
|Day's Range||29.45 - 30.69|
|52 Week Range||25.04 - 64.37|
|Beta (5Y Monthly)||0.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 22, 2022 - Feb. 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.19|
Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.
Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.
BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervalsBiogen paid Ionis a $60 million one-time upfront payment CAMBRIDGE, Mass. and CARLSBAD, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306. The